Back to Search
Start Over
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy
- Source :
- Chemotherapy. 64:110-114
- Publication Year :
- 2019
- Publisher :
- S. Karger AG, 2019.
-
Abstract
- Patients who experience extramedullary relapses (EMR) of multiple myeloma (MM) have an adverse prognosis, also in this era of novel agents like proteasome inhibitors and immunomodulatory drugs. We describe the case of an MM patient with EMR at 2 different sites after allogeneic stem cell transplantation. EMR was refractory to bortezomib, anthracycline, and bendamustine, but the patient achieved long-term complete remission (4 years) with pomalidomide and dexamethasone. This supports the hypothesis that this could be due to the graft-versus-myeloma effect during therapy enhanced by pomalidomide.
- Subjects :
- 0301 basic medicine
Oncology
Bendamustine
medicine.medical_specialty
Anthracycline
medicine.medical_treatment
030106 microbiology
03 medical and health sciences
0302 clinical medicine
Internal medicine
Drug Discovery
medicine
Pharmacology (medical)
Dexamethasone
Multiple myeloma
Pharmacology
Chemotherapy
business.industry
Bortezomib
General Medicine
Pomalidomide
medicine.disease
Transplantation
surgical procedures, operative
Infectious Diseases
030220 oncology & carcinogenesis
business
medicine.drug
Subjects
Details
- ISSN :
- 14219794 and 00093157
- Volume :
- 64
- Database :
- OpenAIRE
- Journal :
- Chemotherapy
- Accession number :
- edsair.doi...........6df24893931afd4c8aaade1eb46f0c8f